A researcher explains the rationale for and goals of her investigations of blood-based biomarkers for Alzheimer’s disease specifically in women.
An All-Fronts Approach to Understanding and Overcoming Alzheimer’s Disease
An early-career Cleveland Clinic researcher has devised a multipronged strategy that integrates advanced computational and experimental approaches to dementia research. The work has attracted $16 million in external grant funding in 2023 alone.
Does Sleep Dysfunction Help Explain Sex Differences in Alzheimer’s Incidence and Progression?
A new project is using tools from sleep research, neuroimaging, and blood and CSF biomarker analysis to study sex-specific influences of sleep and circadian rhythm disruption on neurocognitive decline.
Pilot Study to Target Sex-Based Differences in Alzheimer’s Disease
New research aims to determine whether differences in the blood-based proteome between men and women with Alzheimer’s can help identify biomarkers to improve care for women with the disease.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Markers of Metabolic Syndrome Linked to Cognitive Decline in MCI and Alzheimer’s
Elevations in plasma triglyceride/HDL cholesterol ratio and plasma apolipoprotein A1 were associated with worse cognitive outcomes in a retrospective study of people with mild cognitive impairment or Alzheimer’s disease dementia.
Does Peripheral Inflammation Drive Alzheimer’s Disease Progression?
New NIH-funded research combines analysis of blood-brain barrier changes with detailed characterization of AD-associated immunity changes. The aim is insights that lead to new avenues of therapy.
Deep Learning Framework Unveiled for Identifying Risk Genes and Drug Targets in Alzheimer’s Disease
Application of the novel framework has identified the dyslipidemia medication gemfibrozil as a candidate drug to reduce Alzheimer’s disease risk.
What’s the State of Anti-Amyloid Therapy in the Wake of Initial Clarity AD Findings?
Two brain health experts discuss what the prominent study results mean for the amyloid hypothesis and what to expect next in both clinical practice and the research landscape.
Big Patient Data Analyses Pinpoint Telmisartan as a Candidate Drug for Alzheimer’s in Black Adults
A combination of pharmacoepidemiologic studies and Mendelian randomization genetic analysis revealed preferential protection in Black but not white individuals. The findings support ongoing studies of telmisartan for Alzheimer’s, particularly in racially diverse cohorts.
Alzheimer’s Disease in Women: How Our Understanding Continues to Evolve
Many aspects of Alzheimer’s differ between the sexes. In this Q&A, an expert in the disease among women discusses recent research insights and where the field is likely headed.